8-K: Alkermes to Acquire Avadel for $2.1B, Boosting Sleep Medicine

Alkermes plc announced a definitive agreement to acquire Avadel Pharmaceuticals plc for up to $20.00 per share in cash and contingent value rights, valuing Avadel at approximately $2.1 billion.

Summary

• Alkermes plc will acquire Avadel Pharmaceuticals plc for total consideration of up to $20.00 per share.
• The consideration includes $18.50 per share in cash at closing.
• An additional non-transferable contingent value right (CVR) of $1.50 per share is contingent upon final FDA approval of LUMRYZ for idiopathic hypersomnia in adults by December 31, 2028, and dismissal of specific legal claims.
• The transaction values Avadel at approximately $2.1 billion on a fully diluted basis.
• The acquisition price represents a premium of approximately 38% to Avadel's weighted average trading price over the three months prior to October 22, 2025.
• It also represents a premium of approximately 12% to Avadel's closing price of $17.87 on October 21, 2025.
• The transaction has been approved by the boards of directors of both companies and is expected to close in the first quarter of 2026.
• Alkermes expects to finance the acquisition with cash on hand and new debt.

Sentiment

Score: 8

Explanation: The acquisition offers a substantial premium to Avadel shareholders and is expected to be immediately accretive for Alkermes, significantly expanding its presence in the high-growth sleep medicine market with a differentiated product. While the CVR introduces some contingency, the overall strategic and financial rationale appears strong, supported by positive market uptake of LUMRYZ and the resolution of key litigation.

Positives

• The acquisition of Avadel's FDA-approved product, LUMRYZ, accelerates Alkermes' entry into the sleep medicine market.
• LUMRYZ is the first and only once-at-bedtime oxybate for narcolepsy, offering a differentiated product profile and strong market uptake.
• Approximately 3,100 patients were on LUMRYZ therapy as of June 30, 2025, with new patient starts outpacing a competitor by more than 2:1 since July 2023.
• LUMRYZ net revenues are expected to be $265 $275 million in 2025, with significant growth opportunity in an estimated >50,000 oxybate-eligible narcolepsy patient population in the U.S.
• The transaction is expected to be immediately accretive and enhance Alkermes' revenue growth profile and profitability upon closing.
• Avadel's established commercial infrastructure and experience in rare disease provide a strong foundation for Alkermes' potential launch of alixorexton.
• The combined financial strength will support a broad development strategy for Alkermes' orexin 2 receptor agonists (ALKS 4510 and ALKS 7290 in Phase 1).
• Combined resources will support clinical studies for potential label expansion of LUMRYZ (Phase 3 in idiopathic hypersomnia) and advancement of valiloxybate.
• Integration of Avadel's operations is expected to drive cost synergies and operational efficiencies for Alkermes.
• The acquisition offers a premium of 38% to Avadel's 3-month weighted average trading price and 12% to its closing price on October 21, 2025 (assuming CVR payout).
• The settlement of litigation with Jazz Pharmaceuticals, Inc. on October 21, 2025, positively impacts Avadel's valuation and is a condition for CVR payout.

Negatives

• The CVR is non-transferable and its payment is contingent upon specific milestones (FDA approval for idiopathic hypersomnia and legal event dismissal) by December 31, 2028, with no certainty of achievement.
• If the CVR milestones are not met, the CVR will have zero value.
• No cash confirmation exercise has been undertaken by Alkermes to verify resources for CVR payments, placing CVR holders at risk if resources are unavailable.
• The transaction is expected to be taxable for Avadel shareholders for U.S. federal income tax purposes.
• Potential operational and administrative reorganization of the Avadel Group following completion, including possible reduction in central corporate and support functions.
• Possible consolidation of Avadel's business locations, including its U.S. headquarters in St. Louis, Missouri, into Alkermes' Dublin headquarters or other U.S. locations.

Risks

• There is no certainty that the CVR Milestone (LUMRYZ Approval for idiopathic hypersomnia and Legal Event dismissal) will occur or be achieved prior to the Milestone Expiration (December 31, 2028).
• If the FDA issues a clinical hold on the investigation of the CVR Product for the Indication, the Milestone will not be deemed achieved unless or until no such order is in effect.
• The CVRs are contractual rights only and non-transferable except under limited circumstances, and will not be registered with the SEC or listed for trading.
• Any potential payout of the CVR is subject to various risks and uncertainties related to the development of LUMRYZ and FDA clearances, as described in Avadel's periodic SEC reports.
• The ability of the parties to consummate the acquisition in a timely manner or at all is subject to risks and uncertainties.
• The satisfaction (or waiver) of conditions to the consummation of the acquisition, including shareholder and required regulatory approvals, poses a risk.
• Potential delays in consummating the acquisition could occur.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the acquisition is uncertain.
• The impact of health pandemics on the parties' respective businesses and the actions the parties may take in response thereto could affect the transaction.
• The occurrence of any event, change, or circumstance or condition that could give rise to the termination of the Transaction Agreement is a risk.
• The effect of the announcement or pendency of the acquisition on Avadel's business relationships, operating results, and business generally could be adverse.
• Costs related to the acquisition may be higher than anticipated.
• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the Transaction Agreement or the acquisition is uncertain.
• Alkermes or Avadel's products or product candidates could be shown to be ineffective or unsafe.
• The FDA or regulatory authorities outside the U.S. may not agree with Alkermes or Avadel's regulatory approval strategies or may make adverse decisions regarding its products.
• Alkermes or Avadel may not be able to continue to successfully commercialize their products or support revenue growth from such products.
• There may be a reduction in payment rate or reimbursement for Alkermes or Avadel's products or an increase in related financial obligations to government payers.
• Products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions, or incidents of misuse.

Future Outlook

Alkermes expects the acquisition to be immediately accretive and enhance its revenue growth profile and profitability. The combined organization's financial strength will support a broad development strategy for Alkermes' orexin 2 receptor agonists (ALKS 4510 and ALKS 7290 in Phase 1) and advancement of LUMRYZ label expansion (Phase 3 in idiopathic hypersomnia) and valiloxybate. Integration is anticipated to drive cost synergies and operational efficiencies.

Management Comments

• Richard Pops, CEO of Alkermes: "This transaction represents a pivotal step in Alkermes strategic evolution. With the acquisition of Avadel, we are able to accelerate our commercial entry into the sleep medicine market at a critical inflection point as we prepare to advance alixorexton into a phase 3 program in narcolepsy. Avadel's innovative portfolio, commercial capabilities and dedicated employees provide a strong foundation for growth in this therapeutic area. Enabled by our strong balance sheet, this all-cash transaction enhances our revenue growth profile and is expected to be immediately accretive, reinforcing our commitment to delivering long-term value for shareholders."
• Greg Divis, CEO of Avadel: "This transaction represents a compelling outcome for our shareholders and a powerful validation of our strategy, execution, commercial capabilities and the differentiated value of LUMRYZ. We've built a company deeply committed to transforming the lives of people living with narcolepsy, and I'm incredibly proud of what our team has accomplished. Alkermes shares our passion for innovation and patient impact and, together, we will continue this important work on behalf of people living with central disorders of hypersomnolence."

Industry Context

The acquisition positions Alkermes as a key player in the commercial sleep medicine market, leveraging Avadel's FDA-approved LUMRYZ. This move aligns with Alkermes' existing pipeline focus on central disorders of hypersomnolence, including its orexin 2 receptor agonist candidate, alixorexton, which is preparing for a Phase 3 program in narcolepsy. The transaction enhances Alkermes' capabilities in rare disease and expands its R&D and technology capabilities to advance therapies for underserved patients in this therapeutic area.

Comparison to Industry Standards

• LUMRYZ is highlighted as the "first and only once-at-bedtime oxybate for narcolepsy," indicating a differentiated product profile compared to existing twice-nightly mixed-salts competitors.
• LUMRYZ new patient starts have outpaced the "twice-nightly mixed-salts competitor by more than 2:1 since July 2023," suggesting strong market acceptance relative to established treatments.
• The acquisition is expected to be "immediately accretive" to Alkermes, a common benchmark for successful strategic acquisitions in the pharmaceutical industry.

Management Changes

Corporate Governance

Legal Proceedings

• Dismissal of claims with prejudice by the United States District Court for the District of Delaware in cases involving Jazz Pharmaceuticals, Inc. vs. Avadel CNS Pharmaceuticals, LLC, pursuant to a settlement and license agreement dated October 21, 2025. This is a condition for the CVR payment.

Related Party Transactions

• No new related party transactions are detailed in the filing beyond a general statement that there have been no transactions required to be disclosed under Item 404 of Regulation S-K that have not been otherwise disclosed in the Company SEC Documents filed prior to the date of this filing.

Stakeholder Impact

• Shareholders (Avadel): Will receive $18.50 cash per share and a non-transferable CVR for a potential additional $1.50 per share, representing a significant premium. The transaction is expected to be taxable for U.S. federal income tax purposes.
• Shareholders (Alkermes): Expected to benefit from immediate accretion, enhanced revenue growth, and expanded market presence in sleep medicine.
• Employees (Avadel): Existing employment rights, including pension rights, will be safeguarded. Annual base salary/wage and target annual cash bonus/commissions will be no less favorable for the Benefits Continuation Period (1 year post-Effective Time or until termination). Employee pension and welfare benefits will be no less favorable than for similarly situated Alkermes employees. Potential operational and administrative reorganization, including possible reductions in central corporate and support functions and consolidation of locations.
• Customers (LUMRYZ patients): The combined entity aims to maximize LUMRYZ value and accelerate its reach globally, potentially benefiting more patients.
• Management (Avadel): Non-executive directors intend to resign. Senior management will engage in integration planning.

Next Steps

• Avadel and Alkermes to jointly procure the release of the Rule 2.7 Announcement to a Regulatory Information Service by October 22, 2025.
• Avadel to file preliminary Proxy Statement and Scheme Document with the SEC and Panel by November 12, 2025.
• Avadel to respond to and resolve Panel and SEC comments on the Proxy Statement and Scheme Document.
• Avadel to mail the definitive Proxy Statement to shareholders after SEC and Panel clearance.
• Avadel to convene the Court Meeting and Extraordinary General Meeting (EGM) for shareholder approval of the Scheme and related resolutions.
• Avadel to make necessary applications to the High Court for sanctioning the Scheme.
• Alkermes to make appropriate proposals to participants of Avadel's Company Share Plans.
• Alkermes intends to engage with Avadel's senior management in integration planning, including a review of Avadel's business.
• Alkermes will evaluate the consolidation of some or all of Avadel's business locations.
• Delisting of Avadel Shares from Nasdaq and deregistration under the Exchange Act after the Effective Time.
• Parent and a Rights Agent will enter into a Contingent Value Rights Agreement at or prior to the Effective Time.
• If the Milestone is achieved, Alkermes will deliver a Milestone Notice and payment to the Rights Agent, who will then distribute to CVR holders.

Key Dates

Recommendation

The acquisition offers a substantial premium to Avadel shareholders, indicating a favorable exit. For Alkermes, the deal is strategically sound, immediately accretive, and significantly expands its footprint in a growing therapeutic area with a differentiated, high-growth product (LUMRYZ). The resolution of key litigation and the potential for further label expansion and pipeline development create a strong positive outlook for the combined entity, making it an attractive investment.

Keywords

Alkermes, Avadel Pharmaceuticals, Acquisition, Merger, LUMRYZ, Sodium Oxybate, Narcolepsy, Idiopathic Hypersomnia, Contingent Value Right, CVR, Biopharmaceutical, Sleep Medicine, FDA Approval, Pharmaceutical M&A, Healthcare, Neuroscience